CMIC HOLDINGS announced its launching RENAPRO® L-FBAP Point of Care Test, the newly developed kidney disease biomarker designed to rapidly read L-FABP (L-type Fatty Acid Binding Protein) concentration in human urine, on October 21, 2016.
Immunochromatography method is used for “RENAPRO®L-FABP Point of Care Test”. This rapid L-FABP test enables clinicians to use this test for AKI (Acute Kidney Injury) diagnosis. Test result appears on the test strip only 15 minutes after placing urine sample. Users read and score the test result by comparing color density appeared on the test line with that printed on accompanying reference card.
We will continuously promote further development of product and services to fulfill unmet medical needs and to contribute to patient benefit.
